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penetrating aortic ulcers
Philipp Geisbu¨sch, Drosos Kotelis, Tim F. Weber, Alexander Hyhlik-Du¨rr,
Hans-Ulrich Kauczor, Dittmar Bo¨ckler
Purpose: To present early and midterm results after endovascular stent
graft repair of patients with penetrating aortic ulcers (PAU).
Methods: Between January 1997 and March 2008, a total of 202 patients
received thoracic aortic endografting in our institution, 48 patients (32
men, median age 70 years, range, 48-89) with PAU. A retrospective analysis
of these patients was performed. Thirty-one patients (65%) showed an acute
aortic syndrome (8 contained rupture, 23 symptomatic). Follow-up scheme
included postoperative computed tomography angiography prior to
discharge, at 3, 6, and 12 months, and yearly thereafter. Mean follow-up
was 31.3 months (1.3-112.6).
Results: Technical success was achieved in 93.7%. Primary clinical success
rate was 81.2%. In-hospital mortality was 14.6%. Perioperative mortality
was significantly (P = .036) higher in patients with acute aortic syndrome
compared to asymptomatic patients (22.5% vs 0%). Postoperative complica-
tions occurred in 15 patients (31%), including 2 patients with minor strokes
and 6, respectively, 5 patients with cardiac and/or respiratory complica-
tions. Early endoleaks were observed in 9 patients (19%), late endoleaks in
another 2 patients. Reintervention was necessary in 4 out of 48 patients
(8.4%). The actuarial survival estimates at 1, 3, and 5 years were 78% 
6%, 74%  7%, and 61%  10%, respectively. There was no aortic-related
death during follow-up. Cox regression showed age (hazard ratio [HR];
1.08, P = .036) and a maximum aortic diameter >50 mm (HR, 4.92;
P = .021) as independent predictors of death.
Conclusion: Endovascular treatment of penetrating aortic ulcers is associ-
ated with a relevant morbidity and mortality rate in frequently highly
comorbid patients. Midterm results could prove a sustained treatment
success regarding actuarial survival and aortic-related death. Emergencies
show a significantly worse outcome, but treatment is still warranted in these
symptomatic patients.Use of vacuum assisted closure (VAC) therapy in treating lymphatic
complications after vascular procedures: New approach for lymphoceles
Osama Hamed, Patrick E. Muck, J.M. Smith, Kelli Krallman, Nathan M.
Griffith
Objective: Lymphatic complications, such as lymphocutaneous fistula (LF)
and lymphocele, are relatively uncommon after vascular procedures, but
their treatment represents a serious challenge. Vacuum assisted closure
(VAC) therapy has been reported to be an effective therapeutic option for
LF, but the effectiveness of VAC therapy for lymphoceles is unclear.
Methods: For LF, we apply the VAC directly to the skin defect after extend-
ing it to achieve a clean wound of at least one inch in length. To treat lym-
phocele, we convert the lymphocele to a LF in a sterile fashion by making
a one inch incision in the overlying skin and applying the VAC. The setting
was a community teaching hospital. We used 10 patients that we treated
with VAC therapy for LF (n = 4) and lymphoceles (n = 6).* Full articles available online at www.jvascsurg.org
1078e5884/$34.00
doi:10.1016/S1078-5884(08)00575-3Results: Duration of in-patient stay, duration of in-patient VAC treatment,
duration of out-patient VAC treatment, total duration of VAC treatment.
The median duration of in-patient stay was 4 (range, 0-18) days, the median
duration of in-patient VAC treatment was 1 (range, 0-5) days, the median
duration of out-patient VAC treatment was 16 (range, 7-28) days), and the
median total duration of VAC therapy was 18 (range, 13-29) days. Successful
wound healing was achieved in all patients with no recurrence after VAC
removal. VAC therapy for treatment of both LFs and lymphoceles resulted
in early control of drainage, rapid wound closure, and short hospital stays.
Conclusion: Our results suggest that VAC therapy is a convenient and effec-
tive therapeutic option for both LFs and lymphoceles.Effect of chronic renal insufficiency on outcomes of carotid
endarterectomy
Anton N. Sidawy, Gilbert Aidinian, Owen N. Johnson III, Paul W. White, Kent
J. DeZee, William G. Henderson
Objective: Conflicting data exist regarding the effect of chronic renal insuf-
ficiency (CRI) on carotid endarterectomy (CEA) outcomes. A large database
was used to analyze the effect of CRI, defined by glomerular filtration rate
(GFR), as an independent risk factor of CEA.
Methods: Prospectively collected data regarding CEAs performed at 123
Veterans Affairs Medical Centers as part of the National Surgical Quality
Improvement Program were retrospectively analyzed. Renal function was
used to divide patients into three CRI groups: normal or mild (control; GFR
60 mL/min/1.73 m2), moderate (GFR 30 to 59), and severe (GFR <30).
Bivariate analysis and multivariate logistic regression were used to charac-
terize risk factors and their associations with 30-day morbidity and mortality.
Results: Between Jan 1, 1996, and Dec 31, 2003, 22,080 patients underwent
CEA. Patients missing creatinine levels, already dialysis-dependent, or in
acute renal failure just before surgery were excluded. This left 20,899 avail-
able for analysis, of which 13,965 had a GFR of 60, 6,423 had a GFR of 30 to
59, and 511 had a GFR of <30. The incidence of neurologic complications did
not differ significantly (control, 1.7%; moderate CRI, 1.9%; severe CRI, 2.7%).
The moderate CRI group experienced significantly more cardiac events (1.7%
vs 0.9% for controls, P < .001). This remained predictive in the multivariate
model even adjusting for all other risk factors (adjusted odds ratio [AOR],
1.6; 95% confidence interval [CI], 1.1-2.3; P = .009). The moderate CRI group
also had higher rates of pulmonary complications (2.1% vs 1.3% control; P <
.001; AOR, 1.3; 95% CI, 1.0-1.7; P = .031) but not 30-day mortality (P = .269).
Those with severe CRI had a much higher mortality (3.1% vs 1.0% control, P <
.001), which remained significant in the multivariate model (AOR, 2.7; 95%
CI, 1.6-4.8; P < .001).
Conclusion: Although impaired renal function does not independently
increase the risk of neurologic or infectious complications, CRI is a significant
negative independent risk factor in predicting other outcomes after CEA.
Patients with moderate CRI (GFR, 30-59 mL/min/1.73 m2) are at increased
risk for cardiac and pulmonary morbidity, but not death, and those with
severe CRI (GFR <30 mL/min/1.73 m2) have a much higher operative
mortality. Patients with CRI should be carefully evaluated before CEA to
optimize existing cardiac and pulmonary disease. Understanding this
increased risk may assist the surgeon in preoperative counseling and perio-
perative management.
744 AbstractsLong-term results of carotid artery stenting
Gianmarco de Donato, Carlo Setacci, Koen Deloose, Patrick Peeters, Alberto
Cremonesi, Marc Bosiers
Objective: Data regarding the long-term efficacy of carotid artery stenting
(CAS) are still scarce. As demonstrated by several major randomized
controlled trials (RCT) comparing the efficacy of carotid endarterectomy
(CEA) vs medical therapy, even after successful carotid revascularization
late ipsilateral stroke occurs in 5-13% at 5 years. Therefore, major concerns
also remain about the durability of the CAS procedure in terms of stroke
prevention. The purpose of this study was to review long-term results after
carotid stent implantation in a large cohort of patients.
Methods: This retrospective investigation involved 3179 CAS procedures per-
formed at four European carotid high-volume centers. Echo-duplex scan
using modified velocity criteria to recognize in-stent restenosis (ISR) and
neurological examinations of all patients were carried out every 6 months
after the procedure. Life-table analysis was used to determine freedom
from mortality, stroke-related death, ipsilateral fatal/major stroke, and
any ipsilateral stroke. Freedom from ISR and from reintervention were
also reported. The secondary aim was to identify predictive risk factors
for neurological complications and ISR.
Results: At 5 years freedom from mortality, stroke-related death, ipsilateral
fatal/major stroke, and any stroke rate were 82%, 93.5%, 93.3%, and 91.9%,
respectively. The only predictor for neurological complications was the pres-
ence of neurological symptoms before CAS (hazard ratio 1.38 [CI 1.05, 1.82]
P = .02). Freedom from restenosis at 1, 3, and 5 years was, respectively,
98.4%, 96.1%, and 94%. Uni- and multi-variate analyses showed that stent
characteristics (material/design/free-cell area) were not significantly asso-
ciated with time to in-stent restenosis or time to reintervention.
Conclusion: Our long-term results in a large cohort of patients validated CAS
as a durable procedure for stroke prevention. The annual rate of neurolog-
ical complications after CAS was comparable to that of conventional surgery
as demonstrated by large RCTs involving both symptomatic patients (North
American Symptomatic Carotid Endarterectomy Trial [NASCET] and Euro-
pean Carotid Surgery Trial [ECST]) and asymptomatic patients (Asymptom-
atic Carotid Atherosclerosis Study [ACAS] and Asymptomatic Carotid
Surgery Trial [ACST]).
Risk stratification in critical limb ischemia: Derivation and validation of
a model to predict amputation-free survival using multicenter surgical
outcomes data
Andres Schanzer, Jessica Mega, Judith Meadows, Russell H. Samson, Dennis
F. Bandyk, Michael S. Conte
Background: Patients with critical limb ischemia (CLI) are a heterogeneous
population with respect to risk for mortality and limb loss, complicating clin-
ical decision-making. Endovascular options, compared with bypass, offer
a tradeoff between reduced procedural risk and inferior durability. Risk
stratified data predictive of amputation-free survival (AFS) may improve
clinical decision making and allow for better assessment of new technology
in the CLI population.
Methods: This was a retrospective analysis of prospectively collected data
from patients who underwent infrainguinal vein bypass surgery for CLI.
Two datasets were used: the PREVENT III randomized trial (n = 1404) and
a multicenter registry (n = 716) from three distinct vascular centers (two
academic, one community-based). The PREVENT III cohort was randomly
assigned to a derivation set (n = 953) and to a validation set (n = 451). The
primary endpoint was AFS. Predictors of AFS identified on univariate screen
(inclusion threshold, P < .20) were included in a stepwise selection Cox
model. The resulting five significant predictors were assigned an integer
score to stratify patients into three risk groups. The prediction rule was
internally validated in the PREVENT III validation set and externally vali-
dated in the multicenter cohort.
Results: The estimated 1-year AFS in the derivation, internal validation, and
external validation sets were 76.3%, 72.5%, and 77.0%, respectively. In the
derivation set, dialysis (hazard ratio [HR] 2.81, P < .0001), tissue loss (HR
2.22, P =.0004), age 75 (HR 1.64, P = .001), hematocrit 30 (HR 1.61,
P = .012), and advanced CAD (HR 1.41, P = .021) were significant predictors
for AFS in the multivariable model. An integer score, derived from the b coef-
ficients, was used to generate three risk categories (low  3 [44.4% of
cohort], medium 4-7 [46.7% of cohort], high 8 [8.8% of cohort]). Stratifica-
tion of the patients, in each dataset, according to risk category yielded
three significantly different Kaplan-Meier estimates for 1-year AFS (86%,
73%, and 45% for low, medium, and high risk groups, respectively). Fora given risk category, the AFS estimate was consistent between the deriva-
tion and validation sets.
Conclusion: Among patients selected to undergo surgical bypass for infrain-
guinal disease, this parsimonious risk stratification model reliably identified
a category of CLI patients with a 50% chance of death or major amputation
at 1 year. Calculation of a ‘‘PIII risk score’’ may be useful for surgical deci-
sion making and for clinical trial designs in the CLI population.Cost-effectiveness of endovascular revascularization compared to
supervised hospital-based exercise training in patients with
intermittent claudication: A randomized controlled trial
Sandra Spronk, Johanna L. Bosch, Pieter T. den Hoed, Hermanus F. Veen,
Peter M.T. Pattynama, M.G. Myriam Hunink
Background: The optimal first-line treatment for intermittent claudication
is currently unclear.
Objective: To compare the cost-effectiveness of endovascular revasculari-
zation vs supervised hospital-based exercise in patients with intermittent
claudication during a 12-month follow-up period.
Design: Randomized controlled trial with patient recruitment between
September 2002eseptember 2006 and a 12 month follow-up per patient.
Setting: A large community hospital.
Participants: Patients with symptoms of intermittent claudication due to an
iliac or femoro-popliteal arterial lesion (293) who fulfilled the inclusion
criteria (151) were recruited. Excluded were, for example, patients with
lesions unsuitable for revascularization (illiac or femoropoplitical TASC-
type D and some TASC type-B/C.
Intervention: Participants were randomly assigned to endovascular revascu-
larization (76 patients) or supervised hospital-based exercise (75 aptients).
Measurements: Mean improvement of health-related quality-of-life and
functional capacity over a 12-month period, cumulative 12-month costs,
and incremental costs per quality-adjusted life year (QALY) were assessed
from the societal perspective.
Results: In the endovascular revascularization group, 73% (55 aptients) had
illac disease vs 27% (20 patients). In the supervised hospital-based exercise
group, 68% (51 patients) with femoral disease. There was a non-significant
difference in the adjusted 6- and 12-month EuroQol, rating scale, and
Medical Outcomes Study 36-Item Short Form Health Survey (SF36)-physical
functioning values between the treatment groups. The gain in total mean
QALYs accumulated during 12 months, adjusted for baseline values, was
not statistically different between the groups (mean difference revascular-
ization vs exercise 0.01; 99% CI, V0.05, 0.07; P = .73). The total mean cumu-
lative costs per patient were significantly higher in the revascularization
group (mean difference V2,318; 99% CI V2,130, V2,506; P < .001) and the
incremental cost per QALY was 231,800 V/QALY adjusted for the baseline
variables. One-way sensitivity analysis demonstrated improved effectiveness
after revascularization (mean difference 0.03; CI, 0.02, 0.05; P < .001),
making the incremental costs 75,208 V/QALY.
Conclusion: In conclusion, there was no significant difference in effective-
ness between endovascular revascularization compared to supervised
hospital-based exercise during 12-month follow-up, any gains with endovas-
cular revascularization found were non-significant, and endovascular revas-
cularization costs more than the generally accepted threshold willingness-
to-pay value, which favors exercise.
Clinical Relevance: The role of endovascular revascularization in patients
with intermittent claudication remains controversial. This emphasizes the
need to compare the cost-effectiveness of endovascular revascularization
vs supervised hospital-based exercise in patients with intermittent claudica-
tion during a 12-month follow-up period.Use of vacuum assisted closure (VAC) therapy in treating lymphatic
complications after vascular procedures: New approach for lymphoceles
Osama Hamed, Patrick E. Muck, J.M. Smith, Kelli Krallman, Nathan M.
Griffith
Objective: Lymphatic complications, such as lymphocutaneous fistula (LF)
and lymphocele, are relatively uncommon after vascular procedures, but
their treatment represents a serious challenge. Vacuum assisted closure
(VAC) therapy has been reported to be an effective therapeutic option for
LF, but the effectiveness of VAC therapy for lymphoceles is unclear.
Abstracts 745Methods: For LF, we apply the VAC directly to the skin defect after extend-
ing it to achieve a clean wound of at least one inch in length. To treat lym-
phocele, we convert the lymphocele to a LF in a sterile fashion by making
a one inch incision in the overlying skin and applying the VAC. The setting
was a community teaching hospital. We used 10 patients that we treated
with VAC therapy for LF (n = 4) and lymphoceles (n = 6).
Results: Duration of in-patient stay, duration of in-patient VAC treatment,
duration of out-patient VAC treatment, total duration of VAC treatment.
The median duration of in-patient stay was 4 (range, 0-18) days, the median
duration of in-patient VAC treatment was 1 (range, 0-5) days, the median
duration of out-patient VAC treatment was 16 (range, 7-28) days), and the
median total duration of VAC therapy was 18 (range, 13-29) days. Successful
wound healing was achieved in all patients with no recurrence after VAC
removal. VAC therapy for treatment of both LFs and lymphoceles resulted
in early control of drainage, rapid wound closure, and short hospital stays.
Conclusion: Our results suggest that VAC therapy is a convenient and effec-
tive therapeutic option for both LFs and lymphoceles.Angioplasty with stent graft versus bare stent for recurrent cephalic arch
stenosis in autogenous arteriovenous access for hemodialysis: A
prospective randomized clinical trial
David Shemesh, Ilya Goldin, Ibrahim Zaghal, Daniel Berlowitz, David Raveh,
Oded Olsha
Background: Early recurrent stenosis of the cephalic arch in autogenous
arteriovenous access for hemodialysis is a common problem that requires
stenting to prevent thrombosis. Because the results of stenting areunsatisfactory, we compared the efficacy of stent grafts with bare stents
in these patients.
Methods: All patients who presented with recurrent cephalic arch stenosis
>50% within 3 months of successful balloon angioplasty were randomized
to have angioplasty and stenting with either a bare nitinol stent or a stent
graft. Outcome was assessed by angiography 3 months later. Restenosis
was defined as >50% narrowing of the stent lumen or of the vessel margin
up to 0.5 cm adjacent to the stent. There were no exclusions.
Results: This report includes data on the outcome of 25 consecutive patients
with recurrent cephalic arch stenosis who were treated from April to August
2006. At 3 months, three patients had died and one had undergone a renal
transplant. The 21 patients who had angiography at 3 months had patent
stents. Restenosis rates were seven of 10 (70%) in the bare stent group
and two of 11 (18%) in the stent graft group (P = .024). Life-table analysis
at 3 and 6 months showed that primary patency was 82% in the stent graft
group and 39% in the bare stent group. One-year primary patency was 32%
in the stent graft group and 0% in the bare stent group (P = .0023). During
a mean follow-up of 13.7 months, nine patients died, four in the bare stent
group and five in the stent graft group. Two patients in the stent graft group
had received a renal transplant. The number of interventions per patient-
year was 1.9 in the bare stent group and 0.9 in the stent graft group
(P = .02).
Conclusions: The use of stent grafts in angioplasty for recurrent cephalic
arch stenosis significantly improved short-term restenosis rates and long-
term patency compared with the use of bare stents. The significant improve-
ment that emerged during the study caused accrual of patients to be halted
for ethical reasons. This study altered our usage of stents for venous
stenoses in arteriovenous accesses by eliminating bare nitinol stents in favor
of stent grafts.
